Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP2202 (Laspirin) vs Co-administered Components in Healthy Volunteers
NCT05548387Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin in cardiovascular diseases (CVD) and gastric ulcer (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Sep 2022; status: completed.
02
Drugs
aspirin
03
Conditions
cardiovascular diseases (CVD)gastric ulcer
Beyond the preview
Go deeper on NCT05548387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548387.